Comparative Pharmacology
Head-to-head clinical analysis: BARHEMSYS versus PROMETHAZINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE W CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARHEMSYS versus PROMETHAZINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE W CODEINE PHOSPHATE.
BARHEMSYS vs PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BARHEMSYS (amisulpride) is a selective dopamine D2/D3 receptor antagonist. It also has weak affinity for serotonin 5-HT2A and 5-HT2B receptors, with no significant activity at other dopamine or serotonin receptor subtypes. Its antiemetic effect is primarily mediated through blockade of D2 receptors in the chemoreceptor trigger zone (CTZ).
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, sedative, and antiemetic via central dopamine D2 and muscarinic M1 receptor blockade. Phenylephrine is a sympathomimetic amine that acts as a selective α1-adrenergic receptor agonist, causing vasoconstriction. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects, partly after O-demethylation to morphine.
BARHEMSYS (amisulpride) 10 mg intravenously over 2 minutes, once daily for prevention of postoperative nausea and vomiting.
Each 5 mL of oral solution contains promethazine hydrochloride 6.25 mg, phenylephrine hydrochloride 5 mg, and codeine phosphate 10 mg. Adult dose: 5 mL every 4 to 6 hours as needed. Maximum 30 mL per day.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in most patients.
Promethazine: 9-16 h (adults); prolonged in hepatic impairment. Phenylephrine: 2-3 h (oral); 5-10 min (IV due to rapid redistribution). Codeine: 2.5-3.5 h; active metabolites (morphine) 2-3 h.
Renal excretion accounts for approximately 50% of the dose as unchanged drug; fecal elimination (including biliary) accounts for approximately 30-40%.
Promethazine: ~70% renal as metabolites, minor biliary/fecal. Phenylephrine: ~86-96% renal as metabolites (sulfate and glucuronide conjugates). Codeine: ~90% renal, primarily as morphine and norcodeine conjugates; 5-10% unchanged. Fecal excretion minimal.
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic